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Pertussis is a respiratory infectious disease that has been resurged during the last
decades. The change from the traditional multi-antigen whole-cell pertussis (wP)
vaccines to acellular pertussis (aP) vaccines that consist of a few antigens formulated with
alum, appears to be a key factor in the resurgence of pertussis in many countries. Though
current aP vaccines have helped to reduce the morbidity and mortality associated
with pertussis, they do not provide durable immunity or adequate protection against
the disease caused by the current circulating strains of Bordetella pertussis, which
have evolved in the face of the selection pressure induced by the vaccines. Based
on the hypothesis that a new vaccine containing multiple antigens could overcome
deficiencies in the current aP vaccines, we have designed and characterized a vaccine
candidate based on outer membrane vesicle (OMVs). Here we show that the OMVs
vaccine, but not an aP vaccine, protected mice against lung infection with a circulating
pertactin (PRN)-deficient isolate. Using isogenic bacteria that in principle only differ in
PRN expression, we found that deficiency in PRN appears to be largely responsible for
the failure of the aP vaccine to protect against this circulating clinical isolates. Regarding
the durability of induced immunity, we have already reported that the OMV vaccine is
able to induce long-lasting immune responses that effectively prevent infection with B.
pertussis. Consistent with this, here we found that CD4T cells with a tissue-resident
memory (TRM) cell phenotype (CD44
+CD62LlowCD69+ and/or CD103+) accumulated
in the lungs of mice 14 days after immunization with 2 doses of the OMVs vaccine.
CD4 TRM cells, which have previously been shown to play a critical role sustained
protective immunity against B. pertussis, were also detected in mice immunized
with wP vaccine, but not in the animals immunized with a commercial aP vaccine.
Zurita et al. Pertussis OMVs Vaccine Induces TRM-Cells
The CD4 TRM cells secreted IFN-γ and IL-17 and were significantly expanded through
local proliferation following respiratory challenge of mice with B. pertussis. Our findings
that the OMVs vaccine induce respiratory CD4 TRM cells may explain the ability of this
vaccine to induce long-term protection and is therefore an ideal candidate for a third
generation vaccine against B. pertussis.
Keywords: Bordetella pertussis, pertussis, outer membrane vesicles, TRM cells, pertactin deficient strains,
protection
INTRODUCTION
Although vaccination is the most cost-effective strategy to
prevent life threatening infectious diseases, these diseases
continue to be the main cause of global morbidity and mortality
(Plotkin, 2005). Vaccine preventable diseases (e.g., measles,
tetanus, diphtheria, polio, etc.) are responsible for∼25% of the 10
million deaths that occur annually among children under 5 years
of age. In addition, around 25% of adult deaths (15–59 years) are
still attributed to infectious diseases. Therefore, there is an urgent
need to improve some traditional vaccines of the Expanded
Program on Immunization and to design new vaccines for
emerging, re-emerging or resurgent pathogens (WHO, 2010a,b).
One of the traditional vaccines that needs to be improved is
that designed to prevent the severe respiratory disease whooping
cough or pertussis. During the last decades the incidence of this
disease has increased in adults, adolescents, as well as in children
despite good vaccine coverage (Berti et al., 2014; Clark, 2014).
Individuals at the extreme ends of life may be the most vulnerable
to severe Bordetella pertussis (the etiologic agent of the disease)
infection, though hospitalization can be necessary across all age
groups (Mbayei et al., 2018).
The incidence of pertussis was drastically reduced following
introduction of global immunization with the whole cell pertussis
(wP) vaccine, consisting in a suspension of the causative agent B.
pertussis killed by heat and chemically detoxified (Cherry, 1984).
The wP vaccine was introduced in the 1940 and 1950s and it is
still in use, in developing countries for the pediatric population.
However safety concerns with wP vaccines (Desauziers et al.,
2004; Klein, 2014) and its acceptance diminished in different
countries (Romanus et al., 1987; Klein, 2014). This lead to
development of acellular pertussis (aP) vaccines containing
purified antigenic protein components of B. pertussis (2, 3, or 5
immunogens) (Sato and Sato, 1985; Edwards and Karzon, 1990).
The aP vaccines have a better safety profile and gradually replaced
wP vaccine in many industrialized countries (Zhang et al., 2012).
During the last two decades the epidemiology of pertussis has
changed (Clark, 2014; Tan et al., 2015), with major outbreaks
in many developing countries but also in developed countries
(Hozbor et al., 2009; Clark, 2012), even in those with high rates
of vaccination (He and Mertsola, 2008; Anon, 2010; Clark, 2014;
Mbayei et al., 2018). There have been a number of explanations
for the resurgence of pertussis, including waning of immunity
induced by vaccines, in particular aP vaccines (Koepke et al.,
2014; McGirr and Fisman, 2015), pathogen adaptation to escape
vaccine induced immunity (Mäkelä P. H., 2000; King et al., 2001;
Mooi et al., 2001; He et al., 2003; David et al., 2004; Gzyl et al.,
2004; Bottero et al., 2007; Bowden et al., 2016), and the failure of
pertussis vaccines, in particular aP vaccines, to prevent infection
and spread of B. pertussis.
Regarding pathogen evolution, the first reports were related
to polymorphism in genes coding for proteins included in
the vaccine [pertactin (PRN) and pertussis toxin (PTx) among
others] and later in the pertussis toxin promoter (ptxP) (Advani
et al., 2011; Kallonen et al., 2012). Recently, there has been
an increase in B. pertussis isolates that do not produce some
of the vaccine antigens (Bodilis and Guiso, 2013; Hegerle and
Guiso, 2014; Lam et al., 2014). In particular in US, Canada and
Australia it was reported that PRN-deficient isolates [PRN(-)]
increased substantially in the last years (Lam et al., 2014; Pawloski
et al., 2014; Tsang et al., 2014). These isolates are expected
to be resistant to the phagocytosis mediated by anti-pertactin
antibodies (Hellwig et al., 2003). It has been proposed that
the loss of this vaccine antigen probably provides a selective
advantage for bacterial survival in populations vaccinated with
aP vaccines. Commercial aP vaccines containing PTx, PRN, and
filamentous hemagglutinin (FHA) are not as effective as expected
in controlling the infection caused by the recent circulating
bacteria that do not express PRN (Hegerle et al., 2014). Moreover,
recently it was demonstrated in a mixed infection mouse model
that PRN(-) B. pertussis colonizes the respiratory tract of aP
immunized mice more effectively than the PRN(+) strain, out-
competing the PRN(+) strain (Safarchi et al., 2015).
Regarding waning immunity, it is well known that while wP
vaccines induce potent Th1 and Th17 responses, the current
aP vaccines are inefficient at promoting Th1 responses, but do
induce potent antibody and Th2-polarized responses and weak
Th17 responses (Ross et al., 2013; Brummelman et al., 2015).
Furthermore, immunization with wP vaccines appear to be more
effective than current aP vaccines at inducing immunological
memory and in conferring long-term protection against pertussis
(Brummelman et al., 2015). Recent data has demonstrated that
wP but not aP vaccines induced CD4T memory cells that reside
in the lungs (Allen et al., 2018; Borkner et al., 2018). These
respiratory tissue-resident memory CD4T cells that express
CD44+CD62LlowCD69+ confer long-term protective immunity
against B. pertussis.
Possible solutions to improved control of pertussis disease,
in the short term, include the return to the use of the
wP vaccine in the primary dose and/or add more boosters.
However, adding many boosters implies having both, resources
to sustain the vaccination schedule and pharmaceuticals capable
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of responding to the demands of all countries that require them.
Regarding those countries that switched to aP, it seems difficult
to reintroduce the same wP vaccine since the acceptability of this
vaccine by the population had been lost (Plotkin, 2014).
We have designed a newmulti-antigen aP vaccine formulation
that shares the beneficial properties of current aP vaccines
in terms of biosafety and those of wP vaccines in terms of
immunogenicity and protective capacity (International patent
granted in the USA and in process in other countries,
Application Number: PCT/IB2014/060143) (Roberts et al., 2008;
Asensio et al., 2011; Gaillard et al., 2014). This new acellular
formulation has been obtained from membrane components of
B. pertussis (outer membrane vesicles, OMVs) in which antigens
are presented in their native conformation, with membrane-
associated PAMPs acting as immunostimulatory molecules, such
as in the commercial wP vaccines. We have reported that the
OMVs-based vaccine was capable of inducing a more robust
immune response than current aP vaccines with a Th1/Th17 and
Th2 cellular profile (Bottero et al., 2016), that confers long lasting
protection against B. pertussis (Gaillard et al., 2014).
In this study we have evaluated whether our OMVs vaccine is
capable of overcoming the deficiencies of commercial vaccines
in both controlling infections caused by PRN(-) isolate/strain
and inducing memory immunity. We found that our OMVs-
based formulation has a higher protective capacity against
the PRN(-) bacteria than that induced with a commercial aP
vaccine. We found that CD4T cells with a tissue-resident
memory (TRM) cell phenotype (CD44
+CD62LlowCD69+ and/or
CD103+) accumulated in the lungs of mice after the second
OMVs vaccine immunization. CD4 TRM cells were also
detected in mice immunized with wP vaccine, but not in the
animals immunized with a commercial aP vaccine. The CD4
TRM cell population was significantly expanded through local
proliferation following respiratory challenge of mice with B.
pertussis. These CD4 TRM cells secreted IFN-γ and IL-17 that
have previously been shown to play a critical role in adaptive
immunity against B. pertussis infection. Our findings suggest that
the OMVs-vaccine is an ideal candidate for the development of a
third generation pertussis vaccine.
MATERIALS AND METHODS
Animals
C57BL/6 (8-week-old) mice were obtained from Harlan
Laboratories U.K. or the Comparative Medicine Unit, Trinity
College Dublin and housed in a specific pathogen–free facility.
All animal experiments performed in Dublin were conducted in
accordance with the recommendations and guidelines and under
licenses approved by the Health Products Regulatory Authority
of Ireland in accordance with protocols approved by the Trinity
College Dublin Animal Research Ethics Committee. Animal
experiments using female BALB/c mice with 3–4 weeks of age,
obtained from the Instituto Biológico Argentino (Biol. SAIC,
Argentina) were also performed in Argentina. The studies have
been approved by Ethical Committee for Animal Experiments of
the Faculty of Science at La Plata National University (Argentina,
approval number 004-06-15 and 003-06-15).
Bacterial Strains and Growth Conditions
Bordetella pertussis Tohama phase I strain, its isogenic mutant
strain defective in PRN (Roberts et al., 1991), and PRN-deficient
clinical isolate (Bp935) were used throughout this study. Bp935,
which was kindly provided by CDC (Atlanta) is a representative
PRN(-) isolate obtained from the 2012 Washington (US)
outbreak (Pawloski et al., 2014). PRN deficiency in this isolate
was caused by IS481 insertion into prn gene, and its MLVA-MLST
type is the most prevalent among the isolates from that outbreak
(ptxP3, ptxA1, prn2). Bacteria were grown on Bordet-Gengou
agar (BGA, Difco) supplemented with 10% defibrinated sheep
blood at 36.5◦C for 72 h and plated again on the same medium
for 24 h before each infection.
Isolation and Characterization of Outer
Membrane Vesicles (OMVs)
OMVs were produced and characterized as previously described
(Hozbor et al., 1999; Asensio et al., 2011). Briefly, culture samples
from the decelerating growth phase were centrifuged and the
bacterial pellet obtained was resuspended in 20mM Tris–HCl,
2mM EDTA pH 8.5. The suspension was sonicated (ultrasonic
bath) in cool water for 20min. After two centrifugations
at 10,000 × g for 20min at 4◦C, the supernatant was
pelleted at 100,000 × g for 2 h at 4◦C. This pellet was re-
suspended in Tris buffer (20mM pH 7.6). The samples obtained
were negatively stained for electron microscope examination.
Protein content was estimated by the Bradford method using
bovine serum albumin as standard. The presence of the main
immunogenic proteins in the OMVs was corroborated by
immunoblot assays using specific antibodies as we previously
described (Roberts et al., 2008).
Formulation of OMV-Based Vaccine
The characterized OMVs that range in size from ∼50 to 200
nanometers in diameter were used to formulate the vaccine with
tetanus (5–7 Lf/ dose with a power ≥2 UIA/ml serum) and
diphtheria (1–3 Lf / dose with an output of 0.1 UIA/ml serum)
toxoids as we previously described (Gaillard et al., 2014). The
LPS concentration determined by GC-MS ranged from 0.275 to
0.352 µg per dose of OMV based vaccine. The safety of this
vaccine was evaluated by a mouse weight-gain test (WHO, 2007)
and the murine and human whole-blood IL-6–release assays
(Stoddard et al., 2010; Bottero et al., 2016). To perform the
experiments described below we verified that the OMV based
vaccine prepared by us fulfilled the WHO criteria for safety in
the weight-gain test. The safety of OMV-based vaccines was also
confirmed by human whole-blood assays.
Immunization of Mice
Groups of 4–5 female C57BL/6 or BALB/c mice (discriminated
in the legends to the figures) were immunized with OMVs-
based vaccine formulated as previously described (3 µg total
protein per dose formulated with alum as adjuvant) (Asensio
et al., 2011), 1:50 or 1:10 human dose of aP vaccine BOOSTRIX R©
[GlaxoSmithKline, with composition per human dose: pertussis
toxoid (8 µg), pertactin (2.5 µg), FHA (8 µg), tetanus toxoid
(20 IU), diphtheria toxoid (2 IU), and alum as adjuvant], or
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1:40 human dose of wP vaccine (National Institute of Biological
Standards and Control, South Mimms, UK; NIBSC batch 41S) in
200 µl PBS via intraperitoneal (i.p.) injection using a two-dose
schedule. The i.p route, although not translatable to humans, was
chosen as it allowed us to compare our results with previous
studies on the immunogenicity and protective OMVs-based
pertussis vaccines that used this route of immunization (Gaillard
et al., 2014; Bottero et al., 2016). Two weeks after the second
immunization, mice were sacrificed, and the immune response
was evaluated in lungs and spleen. For protection assays mice
were challenged with B. pertussis by exposure to an aerosol of
5 × 108 bacteria per ml or by intranasal inoculation (sublethal
dose 107-108 CFU 40 µl−1) as is described below. In both case,
mice were killed 1 and/or 2 weeks after challenge.
B. pertussis Respiratory Challenge
For protection assays, mice were challenged with B. pertussis
by exposure to an aerosol of 5 × 108 bacteria per ml or by
intranasal inoculation (sublethal dose 107-108 CFU 40µl−1). For
aerosol challenge, B. pertussis bacteria were grown from a frozen
stock on Bordet Gengou plates containing glycerol and horse
blood (Cruinn) at 36.5◦C. After 3 d of culture, the bacteria were
collected in supplemented Stainer–Scholte medium and cultured
overnight at 36.5◦C in a shaking incubator at 220 rpm. Bacteria
were centrifuged and resuspended in 1% casein solution, and the
OD was measured at 600 nm. B. pertussis infection of C57BL/6
mice was performed by aerosol challenge (BP338 strain; 1 × 108
CFU/ml) administered using a nebulizer (PARI TurboBOY SX)
over 10min (Zhang et al., 2012). The course of infection was
followed by performing CFU counts on lung homogenates at
intervals post-infection (p.i.), as described (Zhang et al., 2012).
For intranasal challenge, mice were infected with a sublethal
dose (107-108 CFU 40 µl−1) of B. pertussis clinical isolate/strain.
Bacterial counts were performed 7 days after the challenge as
described previously (Asensio et al., 2011; Gaillard et al., 2014).
Intravascular Staining for Discriminating
Circulating Cells From Lung-Retained Cells
To discriminate blood-borne circulating cells from lung-localized
cells, we used a well-described approach in which anti-
mouse PE-CD45 Ab (eBioscience) was administered i.v. to
mice 10min before they were euthanized and lungs were
harvested (Gzyl et al., 2004).
Isolation and FACS Analysis of Cells From
Lung or Spleen Tissue
Lung and nasal tissue mononuclear cell suspensions were
prepared by mechanical (chopping with a scalpel) followed by
enzymatic disruption of tissue for 1 h at 37◦C with Collagenase
D (1 mg/ml; Sigma-Aldrich) and DNAse I (20 U/ml; Sigma-
Aldrich). Next, lungs or spleens were passed through a 40-
mm cell strainer to a obtain single-cell suspension, followed
by RBC lysis. The cells were incubated with CD16/CD32
FcgRIII (1:100) to block IgG Fc receptors. Cells were incubated
with LIVE/DEAD Aqua (Invitrogen), followed by surface
staining with fluorochrome-conjugated anti-mouse Abs for
various markers. To detect cytokines, cells were stimulated with
PMA (50 ng/ml) and ionomycin (500 ng/ml) in the presence
of brefeldin A (5 mg/ml) for 4 h at 37◦C. The following
surface Abs were used: CD45R-PE, CD3-BV421, CD44-BV605
(Biolegend), CD62L-PE-CF594 (BD), CD103-BV786, CD4-APC-
eF780, CD69-FITC (eBioscience). For detection of intracellular
cytokines, cells were fixed in 2% PFA and permeabilized with
0.5% saponin (Sigma-Aldrich, Ireland), followed by staining
with IL-17A–PerCP-Cy5.5 and IFN-γ-BV650 (eBiosciences).
Fluorescence minus one or non-specific isotype Abs were used
as controls. Flow cytometric analysis was performed on an
LSR Fortessa, and data were acquired using Diva software
(BD Biosciences). The results were analyzed using FlowJo
software (TreeStar).
Ag-Specific IL-17, IL-5, and IFN-γ
Production by Spleen Cells
Spleens from untreated and immunized mice were passed
through a 40-mm cell strainer to obtain a single-cell suspension.
Spleen cells were cultured with sonicated B. pertussis (sBp;
5 µ/ml), or medium only. After 72 h of incubation, IFN-
γ, IL-5, and IL-17A concentrations were quantified in
supernatants by ELISA. sBp was obtained by sonication of
the bacterial suspension in PBS (1010 CFU/ml) on ice using
ultrasonic homogenizer (10 × 15 s. pulse; Sonopuls Bandelin).
The sonicated bacterial suspension was then centrifuged at
10,000 rpm × 15min. Supernatant was collected and protein
concentration was determined as described above.
Statistical Analysis
For the analysis of CFU counts in animal lungs, before applying
the statistical methods described below we evaluated the
normality of the data by using Shapiro-Wilk test (http://
scistatcalc.blogspot.com.ar/2013/10/shapiro-wilk-test-
calculator.html). After verifying that our CFUs data follows
a normal distribution, we statistically analyzed them by
using one-way analysis of variance (ANOVA) followed by
Bonferroni’s multiple comparison test (GraphPadPrism R©).
Differences were considered to be significant when p < 0.05.
For fluorescence values analysis, we used Mann-Whitney
statistical analysis (p < 0.05). All statistical analysis of data was
performed using GraphPadPrism R© version 6.00 for Windows,
GraphPad R© Software.
RESULTS
OMVs Vaccine Protects Against PRN(-)
B. pertussis Clinical Isolate
We compared the protective capacity of the OMVs vaccine with
that induced with a commercially available aP vaccine against
infection with B. pertussis Tohama phase I strain [ptxP1 variant
and prn1 allele, PRN(+)] or PRN(-) clinical isolate of B. pertussis
Bp935. The OMVs vaccine and the commercial aP vaccine
conferred protective immunity against the B. pertussis Tohama
phase I strain. The bacterial counts in the lungs were significantly
lower in immunized compared with non-immunized mice
(Figure 1A). In contrast, the protective capacity of OMVs vaccine
against PRN(-) isolate was significantly higher than that of the
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 April 2019 | Volume 9 | Article 125
Zurita et al. Pertussis OMVs Vaccine Induces TRM-Cells
FIGURE 1 | Protection against B. pertussis PRN(-) isolate induced with an OMVs vaccine in a mouse model. BALB/c mice were immunized (i.p.) twice, 2 weeks apart.
Mice were challenged with sublethal doses (5 × 107 CFUs/40 µl) of B. pertussis Tohama I PRN(+) (A), B. pertussis 935 PRN(-) (B) or B. pertussis Tohama I PRN(-)
(C) 2 weeks after the second immunization with aP or OMVs vaccine. Three independent experiments were performed for each strain/isolate. Results from one
representative experiment are shown. Results depicted are means of 5 mice per group at 7 days post-challenge. The dashed line indicates the lower limit of detection.
The number of bacteria recovered from mouse lungs is expressed as the log 10 means ± SEM (error bars) of colony forming units (CFU) per lung. Data obtained were
analyzed statistically by using one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test (GraphPadPrism). In (A,B,C) ***Significant
differences with p < 0.001.
commercial aP vaccine (Figure 1B). Mice immunized with the
OMVs had 3 Log10 reduction in colonies 7 days after challenge
with B. pertussis PRN(-) compared with the non-immunized
mice, whereas the CFU counts in the lungs of mice immunized
with the commercial aP vaccine was only reduced by 1 log10
(Figure 1B). Since there may be other unidentified features
other than the absence of PRN in the clinical isolate, we also
evaluated the efficacy of the studied acellular vaccines against
B. pertussis Tohama phase I isogenic bacteria that only differ in
PRN expression. We found that immunization with the OMVs
vaccine significantly (p < 0.001) reduced the bacterial counts in
the lung to near the detection limit of the assay after challenge
with the PRN-defective B. pertussis Tohama mutant (Figure 1C).
Importantly, the protective capacity of commercial aP vaccine
was impaired (at least in 1 log10, p< 0.001) against PRN defective
mutant strain (Figure 1C) compared with that observed again
the wild type strain (Figure 1A). The findings demonstrate that
the current aP vaccine has impaired capacity to protect against
mutant strain or certain circulating strains of B. pertussis that
lack PRN.
CD4 TRM Cell Accumulate in the Lungs of
Mice Immunized With the OMVs Vaccine
We used the murine model to evaluate whether the OMVs-
based candidate pertussis vaccine induced systemic antigen-
specific immune responses and CD4T cells with a TRM cell
phenotype in lungs. The Mills group had already demonstrated
that natural infection or immunization with an wP vaccine
primed respiratory TRM cells, whereas an aP vaccine did not
(Wilk et al., 2017; Allen et al., 2018). Therefore, we performed
experiments comparing the responses with that induced with
the OMV-based vaccine with aP or wP vaccines, with the wP
vaccines acting as positive control. First, we used the murine
respiratory challenge model to confirm that the immunization
with the different vaccines tested in this study were capable of
inducing protection against infection (Figure 2). We found that
two parenteral immunizations with the OMVs vaccine was highly
effective at preventing lung infection; the CFU counts were at or
close to background 7 and 14 days post-challenge (Figure 2). The
protection induced with the OMVs vaccine was similar to that
generated with an wP vaccine (Figure 2 upper panel) and was
significantly better than induced with the aP vaccine (Figure 2,
lower panel).
To examine antigen-specific immune responses to B. pertussis,
spleen cells from immunized mice 14 days after the second
dose were stimulated with sonicated B. pertussis (sBp), cytokines
were quantified in the supernatants by ELISA. The results
revealed that spleen cells from mice immunized with the OMVs
vaccine produced significantly higher concentrations of IFN-γ
and IL-17 than spleen cells from mice immunized with the aP
vaccine (Figure 3). Bordetella pertussis-specific IFN-γ and IL-
17 was also detected in spleen cells from mice immunized with
the wP vaccines. However, antigen-specific IL-17 production
was significantly stronger in mice immunized with the OMVs
vaccine. In contrast, the aP vaccine predominantly induced
antigen-specific IL-5. These data demonstrate that OMVs and wP
vaccine induce a mixed Th1/Th17 response while the current aP
vaccines induce Th2-polarized responses.
We next assessed TRM cell in the lungs (the gating strategy
is shown in Figure S1). In order to discriminate blood borne
circulating leukocytes from lung-retained leukocytes, we used a
validated approach (Gzyl et al., 2004) in which a fluorescently
labeled anti-CD45 antibody (Ab) was administered i.v. to mice
10min prior to sacrifice. Circulating cells become labeled with the
Ab (CD45+), whereas the Ab cannot penetrate the tissue to stain
the lung resident cells and therefore remain unstained (CD45−).
We found that the OMVs vaccine and the wP vaccine (used as
a positive control) induced cytokine-secreting respiratory CD4
TRM cells. There were significant higher number of lung-resident
CD4T cells that expressed the TRM cell markers CD69 and/or
CD103 between in the lungs of mice immunized with OMVs
compared with aP immunized or non-immunized mice (14.02
× 104 ± 2.09 ×104 TRM for OMVs, 14.99 × 10
4 ± 4.70 × 104
TRM for wP, 4.44 × 10
4 ± 0.76 ×104 TRM for aP, 1.59 × 10
4 ±
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FIGURE 2 | Protection of mice against B. pertussis infection induced with the
OMVs vaccine compared with wP and aP vaccines. C57BL/6 mice were
immunized (i.p.) twice, 4 weeks apart, with either wP, aP, or OMVs vaccines or
were non-immunized. Mice were challenge 2 weeks after the second
immunization by aerosol with B. pertussis BP338 strain (1 × 108 CFU/ml)
administered using a nebulizer (PARI TurboBOY SX) over 10min. Results are
shown as the number of bacteria recovered from the mouse lungs at different
time points, expressed as the log10 of the means ± SEM (error bars) of the
CFUs per lung, plotted on the ordinate for the samples from the lungs of the
experimental groups indicated on the abscissa. The experiment involved three
biological replicates with the results from a representative one being
presented. The dotted horizontal line marks the lower limit of detection.
***p<0.001 (ANOVA followed by the Bonferroni post-hoc test).
0.26 × 104 TRM for PBS; Figure 4). To evaluate the functionality
of the induced TRM cell we used intracellular cytokine staining
for IFN-γ or IL-17. The results showed that the immunization
with the wP vaccine or the OMVs vaccine induced IFN-γ or IL-
17-secreting CD4 TRM cells in the lungs. Although the numbers
were highest inmice immunized with the wP vaccine, the number
of cytokine-secreting CD4 TRM cells significantly (p < 0.05)
higher in the lungs of mice immunized with the OMVs vaccine
when compared with the aP vaccine (Figure 5). Furthermore,
CD4T cells with a tissue-resident memory phenotype expanded
significantly (5-fold) after B. pertussis challenge (Figure 6) in
mice vaccinated with the wP or OMVs-based vaccine, but not in
mice immunized with the aP vaccine (Figure 6). These findings
demonstrate that immunization of mice with the OMVs vaccine,
like the wP vaccine but not the aP vaccine, is capable of generating
TRM cells that expand in the lung after B. pertussis challenge.
DISCUSSION
In this study we demonstrated that the OMVs vaccine, like
the wP vaccine, promoted induction of protective immunity
against B. pertussis lung infection in mice and that while both
vaccines were effective at inducing B. pertussis-specific INF-
γ (marker of Th1 cells) and IL-17 (marker of Th17 cells) by
spleen cells, the aP vaccine mainly induced IL-5 (marker of Th2
cells) (Ryan et al., 1998; Bottero et al., 2016). Though antibodies
are known to be involved in protection against pertussis, Th1
and Th17 responses are also crucial for mediating adaptive
immunity and clearance of B. pertussis from the respiratory tract
(Mills et al., 1993; Ryan et al., 1997).
Consistent with previous studies showing that OMV-based
vaccine was capable of conferring both long-lasting immunity
and protection against pertussis (Gaillard et al., 2014), here
we demonstrated that OMV-based vaccine was also effective at
inducing respiratory INF-γ- and IL-17-secreting TRM cells. TRM
cells were also expanded in the lungs of mice immunized with
the wP vaccine, not in mice immunized with a commercial aP
vaccine. The failure of aP vaccine to induce TRM cells, even
using the i.p. route of vaccination, which induces the strongest
immune response in mice, may explain the waning immunity
reported in populations immunized with this vaccine (Klein et al.,
2013; McGirr and Fisman, 2015). The growing evidences that
pertussis affects all age groups suggests that pertussis vaccines,
particularly aP vaccines, do not provide long-lasting immunity.
The induction of respiratory TRM cells in immunized mice with
the OMVs vaccine is an important finding since this memory
CD4T cell population not only provide much more immediate
protection than the anti-pathogen responses conferred by naïve
T-cells, they also could providemore effective immune protection
to the host as demonstrated in other models of infection (Teijaro
et al., 2011; Glennie et al., 2017). CD4 TRM cells have been shown
to play a crucial role in protective immunity against re-infection
with B. pertussis (Wilk et al., 2017) and following vaccination with
aP vaccine formulated with a novel adjuvant, comprising agonists
for TLR2 and intracellular receptor stimulator of interferon
genes (STING) (Allen et al., 2018). Our experiments with the
OMV focused on lung TRM cells, but we do not rule out the
possibility that OMV induces TRM cells in upper respiratory
tract or in the gut. Thus, the immunization with the OMVs as
well as wP vaccine induces long-term memory T cells that could
spread to different parts of the body and a fraction of these
cells would constitute the respiratory TRM cell population. We
found that the CD69+CD4+ TRM cells induced in the lungs by
immunization with OMVs or wP vaccines secreted INF-γ and IL-
17.Moreover, these CD69+CD4+ TRM cells were expanded in the
lungs after B. pertussis challenge in mice immunized with OMVs
or wP vaccine, but not in mice immunized with a commercial
aP vaccine.
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FIGURE 3 | Cytokine production by spleen cells from immunized mice. C57BL/6 mice were immunized as described in Figure 2. Fourteen days after the last
immunization, mice were sacrificed and their spleen cells stimulated with sonicated B. pertussis (sBp) or medium alone (negative control). After 72 h of culture, the
concentrations of IFN-γ, IL-17, and IL-5 were determined in the culture supernatant by ELISA. The results are expressed as mean values (± SEM) of three biological
replicates with each having 4 mice per group. Significant differences were analyzed for each cytokine between non-immunized and immunized mice. *p < 0.05,
ANOVA followed by the Bonferroni post-hoc test.
FIGURE 4 | OMVs and wP vaccines induce CD4 TRM cells in lungs. C57BL/6 mice were immunized as described in Figure 2. Fourteen days post-immunization,
mice were i.v. injected with anti-CD45-PE antibody 10min before euthanasia. Lung tissue was taken from all mice and the T cell response was analyzed by flow
cytometry. Only tissue-resident cells (CD45-PE negative) were included in the analysis. Absolute counts of CD4+ TRM (CD45–, CD44+, CD62L
−, CD69+,
CD103+/–, CD4+). Data are mean ± SEM (n = 4 mice) for CD4+ TRM cells from lungs. *p < 0.05, two-way ANOVA with Bonferroni multiple-comparison test.
Representative flow cytometry plots are shown on the right.
The long-lived IL-17-producing Th17 memory T cells have
also been detected in the respiratory mucosa of B. pertussis-
infected baboons (Warfel and Merkel, 2013). The studies in
this non-human primate model showed that Th17 cells persist
long after pertussis infection and suggest that these cells play
an important role in adaptive immunity to B. pertussis (Warfel
and Merkel, 2013). Our findings suggest that, in contrast to the
aP vaccine, immunization with the OMVs vaccine is an effective
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FIGURE 5 | IFN-γ and IL-17 production by CD4 TRM cells in lungs of immunized mice on the day of challenge. C57BL/6 mice were immunized as described in
Figure 2 and CD4 TRM were quantified in the lungs 2 weeks after the 2nd immunization (the day before challenge) by i.v. labeling with anti-CD45 as described in
Figure 3. Intracellular cytokine staining was performed to quantify IFN-γ and IL-17-secreting TRM cells. Only tissue-resident cells (CD45-PE negative) were included in
the analysis. Results are absolute number of IFN-γ-producing CD4+ CD45− T cells and IL-17-producing CD4+ CD45− T cells in the lung. The bars indicate the
mean ± SEM. *p < 0.05, two-way ANOVA with Bonferroni multiple-comparison test.
approach for inducing lung INF-γ and IL-17-secreting TRM cells
(present study) and for conferring long lasting protection against
B. pertussis colonization (Gaillard et al., 2014). Although the
used i.p. route of immunization is not translatable to humans,
several previous studies, including our own had used this route as
useful and highly reproducible route of systemic immunization
as proof-of-principle in mice. However, we have reported that
intranasal immunization with an aP vaccine formulated with a
novel adjuvant is much more effective than the i.p. route for the
generation of B. pertussis-specific TRM cells (Allen et al., 2018).
Furthermore, studies with B. pertussis OMV have demonstrated
that pulmonary immunization ismore effective than the s.c. route
of immunization for induction of CD103+ TRM cells (Raeven
et al., 2018). Therefore, a “prime and pull” strategy of systemic
priming followed by nasal boosting might be an interesting
approach for induction of systemic and local memory immune
response against B. pertussis (Shin and Iwasaki, 2012).
The OMVs derived from B. pertussis represent an attractive
aP vaccine candidate (Roberts et al., 2008; Asensio et al., 2011;
Ormazabal et al., 2014; Hozbor, 2016) not only because of its
safety and ability to induce protective Th1, Th17 cells (Mills et al.,
1993; Ryan et al., 1997) and TRM cells, but because it contains
a greater number of immunogens in conformations close to
those found in pathogen, when compared with the current aP
vaccines (Hozbor, 2016). This broad immunogenic composition
is an important characteristic of our vaccine candidate since is
expected to exert a lower selection pressure on the circulating
bacterial population than that exerted by the commercial aP
vaccines consisting of only a few antigens. The prevalence of
bacteria that do not express vaccine antigens in regions that only
use aP vaccine provides indirect evidence of selection pressure
being exerting by the aP on the circulating bacterial population
(Bodilis and Guiso, 2013; Hegerle and Guiso, 2014; Lam et al.,
2014). In particular in United States, Canada and Australia it
was reported that PRN(-) strains have increased substantially
in recent years (Lam et al., 2014; Pawloski et al., 2014; Tsang
et al., 2014). The polymorphism in PRN described first and the
spread of PRN-deficient isolates later, have elicited deep concerns
in the healthcare systems since it was hypothesized that these
changes might represent a selective advantage of the bacteria
against immunity induced by the aP vaccines. In particular
PRN-deficient clinical isolates may have an advantage in an
aP-vaccine primed immunity (Martin et al., 2015). It has been
reported that PRN-deficient clinical isolates are able to overcome
the anti-PRN mediated inhibition of macrophage cytotoxicity
in vitro. Moreover, a recent study revealed that recent PRN-
deficient B. pertussis clinical isolates harboring ptxP3 variant
and prn2 allele remain at higher CFUs/lung and are capable
of sustaining infection longer than isolates still producing this
adhesin, in mice immunized with a 3-component aP vaccine
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FIGURE 6 | CD4 TRM cells in lungs of immunized mice after challenge with B. pertussis. C57BL/6 mice were immunized as described in Figure 2 and CD4 TRM were
quantified in the lungs of immunized mice 7 days post-B. pertussis challenge as described in Figure 4. Absolute counts of CD4+ TRM (CD45–, CD44+, CD62L
−,
CD69+, CD103+/–, CD4+) are represented. Data are mean ± SEM (n = 4 mice) for CD4+ TRM cells from lungs. *p < 0.05, two-way ANOVA with Bonferroni
multiple-comparison test. Representative flow cytometry plots are shown on the right.
mice (Hegerle et al., 2014). The authors of such study speculated
that these particular isolates might thus be capable of infecting
immunized individuals at an earlier stage of waning immunity
post-aP vaccine immunization or post-infection, presenting an
advantage when compared to isolates producing PRN. These
findings (Hegerle et al., 2014) are consistent with those on the
higher fitness of PRN negative strain in the immunized mice
recently reported by Safarchi et al. (2015).
Consistent with previous reports (Hegerle et al., 2014; Safarchi
et al., 2015), we found that immunization with commercial aP
vaccine does not protect against PRN(-) isolate as effectively
as against B. pertussis Tohama strain (PRN+). However, the
PRN(-) strain used in this study was a clinical isolate that
is not isogenic to B. pertussis Tohama strain (PRN+) and
contains polymorphisms at other loci that may affect the
fitness of these bacteria. Therefore, we also examined protection
against a PRN defective mutant derived from B. pertussis
Tohama strain. Consistent with previous results (Roberts et al.,
1991), we showed that in addition to PRN, other virulence
factors and key antigens are equally expressed in parental
and derived strain. We found that the commercial aP vaccine
exhibits lower level of protection against the PRN(-) strain
when compared with the parental PRN(+) positive strain.
These results clearly showed the impact of the absence of PRN
expression in the effectiveness of aP vaccine against B. pertussis
when comparisons are made on strains that contain the same
genetic background.
The results obtained here clearly showed that the OMVs
vaccine is more effective than a current commercial aP vaccine
against PRN(-) strains. Therefore the OMV formulation appears
as an attractive vaccine candidate that could replace the current
aP without causing concern on the reactogenicity associated
with wP vaccines because of the proven safety of the OMVs
vaccines (Bottero et al., 2016). Since major limitations of the
current aP are their strong selection pressure exerted on the
circulating bacterial population and their failure to induce
sustained protective immunity, the OMV-based vaccine, that
contains high number of antigens and that induces INF-γ
and IL17-secreting TRM cells, has the potential to replace the
current aP vaccine.
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